{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T10:09:20Z","timestamp":1787738960993,"version":"build-2784847793"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T00:00:00Z","timestamp":1716422400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T00:00:00Z","timestamp":1716422400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1038\/s41375-024-02275-x","type":"journal-article","created":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T17:02:02Z","timestamp":1716483722000},"page":"1638-1641","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Recommendations from the AML molecular MRD expert advisory board"],"prefix":"10.1038","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8182-3057","authenticated-orcid":false,"given":"Stuart","family":"Scott","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4960-5468","authenticated-orcid":false,"given":"Alison","family":"Devonshire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9333-5296","authenticated-orcid":false,"given":"Richard","family":"Dillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Thiede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5481-2555","authenticated-orcid":false,"given":"Nicholas C. P.","family":"Cross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen E.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leandro","family":"Lo Cascio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katya","family":"Mokretar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8256-9350","authenticated-orcid":false,"given":"Nicola","family":"Potter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher S.","family":"Hourigan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1618-230X","authenticated-orcid":false,"given":"Jerald","family":"Radich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Corner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Laloux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma","family":"Halliday","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Dilks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Morrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katelyn","family":"Gilmour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Cartwright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liam","family":"Whitby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,23]]},"reference":[{"key":"2275_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-023-01424-6","volume":"16","author":"RS Bhansali","year":"2023","unstructured":"Bhansali RS, Pratz KW, Lai C. Recent advances in targeted therapies in acute myeloid leukemia. J Hematol Oncol. 2023;16:1\u201327.","journal-title":"J Hematol Oncol"},{"key":"2275_CR2","unstructured":"United States Food and Drug Administration. Hematologic Malignancies: Regulatory Considerations for Use of Minimal Residual Disease in Development of Drug and Biological Products for Treatment Guidance for Industry. 2020 Jan. United States Food and Drug Administration. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/hematologic-malignancies-regulatory-considerations-use-minimal-residual-disease-development-drug-and (accessed 4 Aug 2023)."},{"key":"2275_CR3","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1182\/blood-2017-09-801498","volume":"131","author":"GJ Schuurhuis","year":"2018","unstructured":"Schuurhuis GJ, Heuser M, Freeman S, B\u00e9n\u00e9 M-C, Buccisano F, Cloos J, et al. Minimal\/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2018;131:1275\u201391.","journal-title":"Blood"},{"key":"2275_CR4","unstructured":"UK NEQAS LI Home Page - Measurable Residual Disease for AML by Molecular Methods (Pilot - Not Accredited). https:\/\/www.ukneqasli.co.uk\/eqa-pt-programmes\/molecular-haemato-oncology-programmes\/measurable-residual-disease-for-aml-by-molecular-methods-pilot-not-accredited\/ (accessed 4 Aug 2023)."},{"key":"2275_CR5","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/bjh.17521","volume":"194","author":"S Scott","year":"2021","unstructured":"Scott S, Cartwright A, Francis S, Whitby L, Sanzone AP, Mulder A, et al. Assessment of droplet digital polymerase chain reaction for measuring BCR-ABL1 in chronic myeloid leukaemia in an international interlaboratory study. Br J Haematol. 2021;194:53\u201360.","journal-title":"Br J Haematol"},{"key":"2275_CR6","doi-asserted-by":"publisher","first-page":"3686","DOI":"10.1182\/bloodadvances.2022009379","volume":"7","author":"S Scott","year":"2023","unstructured":"Scott S, Dillon R, Thiede C, Sadiq S, Cartwright A, Clouston HJ, et al. Assessment of acute myeloid leukemia molecular measurable residual disease testing in an interlaboratory study. Blood Adv. 2023;7:3686\u201394.","journal-title":"Blood Adv"},{"key":"2275_CR7","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1182\/blood-2010-06-291641","volume":"116","author":"HE White","year":"2010","unstructured":"White HE, Matejtschuk P, Rigsby P, Gabert J, Lin F, Lynn Wang Y, et al. Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA. Blood. 2010;116:111\u201317.","journal-title":"Blood"},{"key":"2275_CR8","unstructured":"Leaders and aspiring leaders in healthcare science - National Physical Laboratory. https:\/\/www.npl.co.uk\/leaders-in-healthcare-science (accessed 10 Oct 2023)."},{"key":"2275_CR9","doi-asserted-by":"publisher","first-page":"e55","DOI":"10.3324\/haematol.2015.133819","volume":"101","author":"T Alpermann","year":"2016","unstructured":"Alpermann T, Schnittger S, Eder C, Dicker F, Meggendorfer M, Kern W, et al. Molecular subtypes of NPM1 mutations have different clinical profiles, specific patterns of accompanying molecular mutations and varying outcomes in intermediate risk acute myeloid leukemia. Haematologica. 2016;101:e55\u20138.","journal-title":"Haematologica"},{"key":"2275_CR10","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1001\/jama.2023.1363","volume":"329","author":"LW Dillon","year":"2023","unstructured":"Dillon LW, Gui G, Page KM, Ravindra N, Wong ZC, Andrew G, et al. DNA sequencing to detect residual disease in adults with acute myeloid leukemia prior to hematopoietic cell transplant. JAMA. 2023;329:745\u201355.","journal-title":"JAMA"},{"key":"2275_CR11","unstructured":"International Organization for Standardization. ISO 17034:2016\u2014General requirements for the competence of reference material producers. Available from: https:\/\/www.iso.org\/standard\/29357.html (accessed 9 Aug 2023)."},{"key":"2275_CR12","unstructured":"International Organization for Standardization. ISO 13485:2016\u2014Medical devices\u2014Quality management systems\u2014Requirements for regulatory purposes. Available from: https:\/\/www.iso.org\/standard\/59752.html (accessed 9 Aug 2023)."},{"key":"2275_CR13","unstructured":"WHO. Expert Committee on Biological Standardization WHO Expert Committee on Biological Standardization: Fifty-ninth report. WHO Technical Report Series 2012;1-240. Available from: https:\/\/www.who.int\/groups\/expert-committee-on-biological-standardization."},{"key":"2275_CR14","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1038\/s41375-022-01607-z","volume":"36","author":"HE White","year":"2022","unstructured":"White HE, Salmon M, Albano F, Andersen CSA, Balabanov S, Balatzenko G, et al. Standardization of molecular monitoring of CML: results and recommendations from the European treatment and outcome study. Leukemia. 2022;36:1834\u201342.","journal-title":"Leukemia"},{"key":"2275_CR15","unstructured":"International Organization for Standardization. ISO 17511:2020 In vitro diagnostic medical devices \u2014 Requirements for establishing metrological traceability of values assigned to calibrators, trueness control materials and human samples. 2020. Available from: https:\/\/www.iso.org\/standard\/69984.html (accessed 9 Aug 2023)."}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02275-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02275-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02275-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T23:07:37Z","timestamp":1719875257000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02275-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,23]]},"references-count":15,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["2275"],"URL":"https:\/\/doi.org\/10.1038\/s41375-024-02275-x","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,23]]},"assertion":[{"value":"21 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Whilst the diverse composition of the panel brought a breadth of expertise and perspectives, it also introduced potential conflicts of interest, particularly regarding the commercial providers. These entities may have a vested interest in the outcomes of the advisory panel due to their affiliations and the nature of their businesses. Each member has disclosed their respective affiliations with commercial bodies. The discussion was led by individuals from non-commercial entities and all recommendations and findings have been derived through consensus and with the commitment to advancing clinical and laboratory practice. These disclosures have been made explicit to uphold transparency and integrity in the reporting of the panel\u2019s findings.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}